Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.46 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.46 |
| ▸ | RPS17 | P08708 | 1/20 | 0.46 |
| ▸ | RPSA | P08865 | 1/20 | 0.46 |
| ▸ | RPS2 | P15880 | 1/20 | 0.46 |
| ▸ | RPL35A | P18077 | 1/20 | 0.46 |
| ▸ | RPL7 | P18124 | 1/20 | 0.46 |
| ▸ | RPL17 | P18621 | 1/20 | 0.46 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.46 |
| ▸ | RPS3 | P23396 | 1/20 | 0.46 |
| ▸ | RPS12 | P25398 | 1/20 | 0.46 |
| ▸ | RPL13 | P26373 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397483 | 1.00 | CYP3A4 (0.52) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL11043104 | 0.81 | CYP3A4 (0.69) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| Bromide SCHEMBL11044241 | 0.81 | CYP3A4 (0.67) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL20413868 | 0.77 | CYP3A4 (0.57) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL12850350 | 0.74 | CYP3A4 (0.72) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL4744337 | 0.74 | CYP3A4 (0.72) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL2321619 | 0.73 | CYP3A4 (0.77) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL16009977 | 0.72 | CYP3A4 (0.72) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL16011473 | 0.72 | CYP3A4 (0.91) | CYP3A4MAPTLMNATSHRSMN1; SMN2 | |
| SCHEMBL16011501 | 0.72 | CYP3A4 (0.71) | CYP3A4MAPTLMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2018140580-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | 2C TECH CORP. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140580-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | 2C TECH CORP. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | UACA, CRYAA, CRYAB | CYP3A4 4717/4885MAPT 231/4885LMNA 1522/4885 |
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | CHRNA1, CHRNB1, NPY1R | CYP3A4 3264/4885MAPT 232/4885LMNA 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.